{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T11:06:17Z","timestamp":1784977577204,"version":"3.55.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.euf.2018.08.010","type":"journal-article","created":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T21:27:30Z","timestamp":1535578050000},"page":"472-480","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Unmet Clinical Needs and Future Perspectives in Non\u2013muscle-invasive Bladder Cancer"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5237-0888","authenticated-orcid":false,"given":"Riccardo","family":"Campi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Seisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2018.08.010_bib0005","unstructured":"Yock PG, Zenios SM, Makower JB, et al. Biodesign: the process of innovating medical technologies. ed 2. UK: Cambridge University Press; 2015. ISBN 978-1-107-08735-4. www.ebiodesign.org"},{"key":"10.1016\/j.euf.2018.08.010_bib0010","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","article-title":"Bladder cancer","volume":"388","author":"Kamat","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.euf.2018.08.010_bib0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0146-0005(97)80013-4","article-title":"Evidence-based medicine","volume":"21","author":"Sackett","year":"1997","journal-title":"Semin Perinatol"},{"key":"10.1016\/j.euf.2018.08.010_bib0020","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.eururo.2014.01.006","article-title":"The economics of bladder cancer: costs and considerations of caring for this disease","volume":"66","author":"Svatek","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.08.010_bib0025","unstructured":"Babjuk M, Burger M, Comp\u00e9rat E, et al. European Association of Urology (EAU) Guidelines on non-muscle-invasive bladder cancer. Ed. 2018. Edn. presented at the EAU Annual Congress Copenhagen 2018. Arnhem, The Netherlands: EAU Guidelines Office; 2018. ISBN 978-94-92671-01-1. Available at http:\/\/uroweb.org\/guideline\/non-muscle-invasive-bladder-cancer\/"},{"key":"10.1016\/j.euf.2018.08.010_bib0030","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO Guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.08.010_bib0035","first-page":"1240","article-title":"Bladder cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc","volume":"15","author":"Spiess","year":"2017","journal-title":"Netw"},{"key":"10.1016\/j.euf.2018.08.010_bib0040","doi-asserted-by":"crossref","unstructured":"Hendricksen K, Aziz A, Bes P, et al. Discrepancy between European Association of Urology Guidelines and daily practice in the management of non\u2013muscle-invasive bladder cancer: results of a European survey. Eur Urol Focus. In press. https:\/\/doi.org\/10.1016\/j.euf.2017.09.002","DOI":"10.1016\/j.euf.2017.09.002"},{"key":"10.1016\/j.euf.2018.08.010_bib0045","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.molmed.2017.08.003","article-title":"Precision oncology: the road ahead","volume":"23","author":"Senft","year":"2017","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.euf.2018.08.010_bib0050","doi-asserted-by":"crossref","unstructured":"Schwartzberg L, Kim ES, Liu D, Schrag D. Precision oncology: who, how, what, when, and when not? 2017 ASCO Annual Meeting. DOI: 10.14694\/EDBK_174176. Available at: https:\/\/meetinglibrary.asco.org\/record\/137923\/edbook#fulltext","DOI":"10.1200\/EDBK_174176"},{"key":"10.1016\/j.euf.2018.08.010_bib0055","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","article-title":"Bladder cancer incidence and mortality: a global overview and recent trends","volume":"71","author":"Antoni","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.08.010_bib0060","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.08.010_bib0065","doi-asserted-by":"crossref","first-page":"17022","DOI":"10.1038\/nrdp.2017.22","article-title":"Bladder cancer","volume":"3","author":"Sanli","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.euf.2018.08.010_bib0070","unstructured":"Mottet N, Bellmunt J, Briers E, et al. European Association of Urology (EAU)\u2014European Society for Radiotherapy & Oncology (ESTRO)\u2014European Society of Urogenital Radiology (ESUR)\u2014International Society of Geriatric Oncology (SIOG), Guidelines on prostate cancer, version 2017. http:\/\/uroweb.org\/guideline\/prostate-cancer\/"},{"key":"10.1016\/j.euf.2018.08.010_bib0075","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.euf.2014.12.006","article-title":"Smoking status is not sufficient to accurately target patients who would benefit from screening for bladder and kidney cancer","volume":"1","author":"Roupr\u00eat","year":"2015","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2018.08.010_bib0080","doi-asserted-by":"crossref","unstructured":"Comp\u00e9rat EM, Burger M, Gontero P, et al. Grading of urothelial carcinoma and the new \u201cWorld Health Organisation classification of tumours of the urinary system and male genital organs 2016\u2019\u2019. Eur Urol Focus. In press. https:\/\/doi.org\/10.1016\/j.euf.2018.01.003","DOI":"10.1016\/j.euf.2018.01.003"},{"key":"10.1016\/j.euf.2018.08.010_bib0085","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1200\/JCO.2014.57.6967","article-title":"Improving selection criteria for early cystectomy in high-grade t1 bladder cancer: a meta-analysis of 15,215 patients","volume":"33","author":"Martin-Doyle","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2018.08.010_bib0090","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.eururo.2017.03.010","article-title":"Genetic alterations in the molecular subtypes of bladder cancer: illustration in the Cancer Genome Atlas dataset","volume":"72","author":"Choi","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.08.010_bib0095","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2017.05.032","article-title":"Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets","volume":"72","author":"Pietzak","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.08.010_bib0100","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.eururo.2017.06.022","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma: a step closer to clinical translation?","volume":"72","author":"Rentsch","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.08.010_bib0105","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrc3817","article-title":"Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity","volume":"15","author":"Knowles","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.euf.2018.08.010_bib0110","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","author":"The Cancer Genome Atlas Research Network","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.euf.2018.08.010_bib0115","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1158\/1078-0432.CCR-14-1215","article-title":"Invasive bladder cancer: genomic insights and therapeutic promise","volume":"21","author":"Kim","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euf.2018.08.010_bib0120","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","article-title":"Comprehensive transcriptional analysis of early-stage urothelial carcinoma","volume":"30","author":"Hedegaard","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.euf.2018.08.010_bib0125","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/1756287217720401","article-title":"Optical improvements in the diagnosis of bladder cancer: implications for clinical practice","volume":"9","author":"Schubert","year":"2017","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.euf.2018.08.010_bib0130","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.21037\/tau.2017.11.29","article-title":"The contemporary role and impact of urine-based biomarkers in bladder cancer","volume":"6","author":"Duquesne","year":"2017","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.euf.2018.08.010_bib0135","doi-asserted-by":"crossref","unstructured":"Zhang S, Wang Y, Bondaruk J, et al. Detection of bladder cancer in urine sediments by a novel multicolor fluorescence in situ hybridization (quartet) test. Eur Urol Focus. In press. https:\/\/doi.org\/10.1016\/j.euf.2018.01.017","DOI":"10.1016\/j.euf.2018.01.017"},{"key":"10.1016\/j.euf.2018.08.010_bib0140","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3233\/BLC-170140","article-title":"Liquid biopsy-analysis of circulating tumor DNA (ctDNA) in bladder cancer","volume":"4","author":"Todenh\u00f6fer","year":"2018","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.euf.2018.08.010_bib0145","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nrurol.2015.100","article-title":"Developing proteomic biomarkers for bladder cancer: towards clinical application","volume":"12","author":"Frantzi","year":"2015","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euf.2018.08.010_bib0150","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/ijc.30016","article-title":"Biomarkers in bladder cancer: a metabolomic approach using in vitro and ex vivo model systems","volume":"139","author":"Rodrigues","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.euf.2018.08.010_bib0155","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/iju.13509","article-title":"Prediction models for progression of non-muscle-invasive bladder cancer: a review","volume":"25","author":"Fujii","year":"2018","journal-title":"Int J Urol"},{"key":"10.1016\/j.euf.2018.08.010_bib0160","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.eururo.2015.01.032","article-title":"Prognostic and prediction tools in bladder cancer: a comprehensive review of the literature","volume":"68","author":"Kluth","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.08.010_bib0165","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/bju.13760","article-title":"Guideline of guidelines: non-muscle-invasive bladder cancer","volume":"119","author":"Woldu","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2018.08.010_bib0170","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.eururo.2015.07.034","article-title":"Fine-tuning risk stratification for non-muscle-invasive bladder cancer","volume":"69","author":"Black","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.08.010_bib0175","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.juro.2014.02.2573","article-title":"Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer","volume":"192","author":"Kamat","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.08.010_bib0180","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus Calmette-Gu\u00e9rin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.08.010_bib0185","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.eururo.2017.05.040","article-title":"Prognostic impact of a 12-gene progression score in non-muscle-invasive bladder cancer: a prospective multicentre validation study","volume":"72","author":"Dyrskj\u00f8t","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.08.010_bib0190","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2018.08.010_bib0195","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.eururo.2018.02.014","article-title":"Repeat transurethral resection in non-muscle-invasive bladder cancer: a systematic review","volume":"73","author":"Cumberbatch","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.08.010_bib0200","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.euf.2016.12.004","article-title":"Current evidence of transurethral en-bloc resection of nonmuscle invasive bladder cancer","volume":"3","author":"Kramer","year":"2017","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2018.08.010_bib0205","article-title":"MP 83-18 Transurethral endoscopic submucosal dissection of bladder tumor with hybrid knife\u201431 cases report","volume":"199","author":"Zhu","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.08.010_bib0210","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/MOU.0000000000000370","article-title":"Can we improve transurethral resection of the bladder tumour for nonmuscle invasive bladder cancer?","volume":"27","author":"Liem","year":"2017","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.euf.2018.08.010_bib0215","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00345-013-1142-z","article-title":"The use of immediate postoperative instillations of intravesical chemotherapy after TURBT of NMIBC among European countries","volume":"32","author":"Palou-Redorta","year":"2014","journal-title":"World J Urol"},{"key":"10.1016\/j.euf.2018.08.010_bib0220","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrurol.2017.16","article-title":"BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG","volume":"14","author":"Kamat","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euf.2018.08.010_bib0225","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrurol.2014.15","article-title":"The mechanism of action of BCG therapy for bladder cancer\u2014a current perspective","volume":"11","author":"Redelman-Sidi","year":"2014","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euf.2018.08.010_bib0230","unstructured":"Administration UFD. In: Services UDoHaH, editor. In BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and bio- logics for treatment guidance for industry. Silver Spring, MD: Office of Communications, Division of Drug Information; 2018. p. 1\u201310."},{"key":"10.1016\/j.euf.2018.08.010_bib0235","doi-asserted-by":"crossref","unstructured":"Li R, Spiess PE, Kamat AM. Treatment options for patients with recurrent tumors after BCG therapy: are we ignoring the obvious? Eur Urol. In press. https:\/\/doi.org\/10.1016\/j.eururo.2018.04.012","DOI":"10.1016\/j.eururo.2018.04.012"},{"key":"10.1016\/j.euf.2018.08.010_bib0240","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.urolonc.2017.06.043","article-title":"Current clinical trials in non-muscle invasive bladder cancer","volume":"35","author":"Siddiqui","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2018.08.010_bib0245","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.urolonc.2017.12.020","article-title":"Role of immunotherapy in bacillus Calmette-Gu\u00e9rin-unresponsive non-muscle invasive bladder cancer","volume":"36","author":"Mukherjee","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2018.08.010_bib0250","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/iju.13538","article-title":"Bacillus Calmette-Gu\u00e9rin strain differences as the basis for immunotherapies against bladder cancer","volume":"25","author":"Miyazaki","year":"2018","journal-title":"Int J Urol"},{"key":"10.1016\/j.euf.2018.08.010_bib0255","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3233\/BLC-160056","article-title":"The future of intravesical drug delivery for non-muscle invasive bladder cancer","volume":"2","author":"Douglass","year":"2016","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.euf.2018.08.010_bib0260","doi-asserted-by":"crossref","unstructured":"Klaassen Z, Kamat AM, Kassouf W, et al. Treatment strategy for newly diagnosed T1 high-grade bladder urothelial carcinoma: new insights and updated recommendations. Eur Urol. In press. https:\/\/doi.org\/10.1016\/j.eururo.2018.06.024","DOI":"10.1016\/j.eururo.2018.06.024"},{"key":"10.1016\/j.euf.2018.08.010_bib0265","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.eururo.2017.10.003","article-title":"Predicting response to intravesical bacillus Calmette-Gu\u00e9rin immunotherapy: are we there yet?","volume":"73","author":"Kamat","year":"2018","journal-title":"A systematic review. Eur Urol"},{"key":"10.1016\/j.euf.2018.08.010_bib0270","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.eururo.2010.11.031","article-title":"NRAMP1 and hGPX1 gene polymorphism and response to bacillus Calmette-Gu\u00e9rin therapy for bladder cancer","volume":"59","author":"Chiong","year":"2011","journal-title":"Eur Urol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456918302293?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456918302293?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:48:43Z","timestamp":1762498123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456918302293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S2405456918302293"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2018.08.010","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unmet Clinical Needs and Future Perspectives in Non\u2013muscle-invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2018.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}